CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Fenofibrate

非诺贝特 杂质对照品Fenofibrate Impurities

EP37 个杂质条目37 impurity entries

本页汇总 非诺贝特 的 37 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 37 impurity reference standards of Fenofibrate with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 非诺贝特(Fenofibrate)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets
    Journal of pharmaceutical and biomedical analysis · 2008 · Kadav AA, Vora DN  ·  PMID 18583084  ·  DOI
  2. 杂质研究Impurity studiesUnivariate and multivariate assisted spectrophotometric methods for determination of rosuvastatin calcium and fenofibrate in bulk powders and tablets along with their degradation products
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2021 · Hegazy MA et al.  ·  PMID 33223434  ·  DOI
  3. 杂质研究Impurity studiesHigh drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods
    Drug delivery · 2016 · Hong S et al.  ·  PMID 24853963  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and Validation of Isocratic RP-UHPLC Method for Assay of Fenofibrate Tablet
    Biomedical chromatography : BMC · 2026 · Yadav J et al.  ·  PMID 42517867  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms
    Indian journal of pharmaceutical sciences · 2008 · Jain N et al.  ·  PMID 20046730  ·  DOI

非诺贝特 —— 原料药与杂质对照品Fenofibrate — drug substance & impurities

共 38 个条目(含原料药本体)38 items incl. the drug substance
Fenofibrate structure
EP原料药 APIAPI
非诺贝特Fenofibrate
Fenofibrate
CAS No.49562-28-9
Chemical FormulaC20H21ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 1 (Fenofibrate EP Impurity A) structure
EPA
非诺贝特杂质1 (非诺贝特EP杂质A)Fenofibrate Impurity 1 (Fenofibrate EP Impurity A)
Fenofibrate Impurity 1 (Fenofibrate EP Impurity A)
CAS No.42019-78-3
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 2 Sodium Salt (Fenofibrate EP Impurity B Sodium Salt) structure
EPB
非诺贝特杂质2 钠盐 (非诺贝特EP杂质B 钠盐)Fenofibrate Impurity 2 Sodium Salt (Fenofibrate EP Impurity B Sodium Salt)
Fenofibrate Impurity 2 Sodium Salt (Fenofibrate EP Impurity B Sodium Salt)
CAS No.258834-37-6
Chemical FormulaC17H14ClO4-·Na+
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 2 (Fenofibrate EP Impurity B) structure
EPB
非诺贝特杂质2 (非诺贝特EP杂质B)Fenofibrate Impurity 2 (Fenofibrate EP Impurity B)
Fenofibrate Impurity 2 (Fenofibrate EP Impurity B)
CAS No.42017-89-0
Chemical FormulaC17H15ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 2 Choline (Fenofibrate EP Impurity B Choline) structure
EPB
非诺贝特杂质2 胆碱 (非诺贝特EP杂质B 胆碱)Fenofibrate Impurity 2 Choline (Fenofibrate EP Impurity B Choline)
Fenofibrate Impurity 2 Choline (Fenofibrate EP Impurity B Choline)
CAS No.856676-23-8
Chemical FormulaC17H14ClO4-·C5H14NO+
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 3(Fenofibrate EP Impurity C) structure
EPC
非诺贝特杂质3(非诺贝特EP杂质C)Fenofibrate Impurity 3(Fenofibrate EP Impurity C)
Fenofibrate Impurity 3(Fenofibrate EP Impurity C)
CAS No.217636-47-0
Chemical FormulaC17H15ClO3
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 4 (Fenofibrate EP Impurity D) structure
EPD
非诺贝特杂质4 (非诺贝特EP杂质D)Fenofibrate Impurity 4 (Fenofibrate EP Impurity D)
Fenofibrate Impurity 4 (Fenofibrate EP Impurity D)
CAS No.42019-07-8
Chemical FormulaC18H17ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 5(Fenofibrate EP Impurity E) structure
EPE
非诺贝特杂质5(非诺贝特EP杂质E)Fenofibrate Impurity 5(Fenofibrate EP Impurity E)
Fenofibrate Impurity 5(Fenofibrate EP Impurity E)
CAS No.42019-08-9
Chemical FormulaC19H19ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 6(Fenofibrate EP Impurity F) structure
EPF
非诺贝特杂质6(非诺贝特EP杂质F)Fenofibrate Impurity 6(Fenofibrate EP Impurity F)
Fenofibrate Impurity 6(Fenofibrate EP Impurity F)
CAS No.154356-96-4
Chemical FormulaC16H15ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 7(Fenofibrate EP Impurity G) structure
EPG
非诺贝特杂质7(非诺贝特EP杂质G)Fenofibrate Impurity 7(Fenofibrate EP Impurity G)
Fenofibrate Impurity 7(Fenofibrate EP Impurity G)
CAS No.217636-48-1
Chemical FormulaC24H27ClO6
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 8 structure
8
非诺贝特杂质8Fenofibrate Impurity 8
Fenofibrate Impurity 8
CAS No.1871-38-1
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 10 structure
10
非诺贝特杂质10Fenofibrate Impurity 10
Fenofibrate Impurity 10
CAS No.1797121-54-0
Chemical FormulaC21H21ClO6
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 11 structure
11
非诺贝特杂质11Fenofibrate Impurity 11
Fenofibrate Impurity 11
CAS No.61002-27-5
Chemical FormulaC17H16O5
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 12 structure
12
非诺贝特杂质12Fenofibrate Impurity 12
Fenofibrate Impurity 12
CAS No.2985-79-7
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 13 structure
13
非诺贝特杂质13Fenofibrate Impurity 13
Fenofibrate Impurity 13
CAS No.78589-10-3
Chemical FormulaC14H11ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 14 structure
14
非诺贝特杂质14Fenofibrate Impurity 14
Fenofibrate Impurity 14
CAS No.62810-39-3
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 15 structure
15
非诺贝特杂质15Fenofibrate Impurity 15
Fenofibrate Impurity 15
CAS No.32363-45-4
Chemical FormulaC14H11ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 19 structure
19
非诺贝特杂质19Fenofibrate Impurity 19
Fenofibrate Impurity 19
CAS No.62809-68-1
Chemical FormulaC19H19ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 20 structure
20
非诺贝特杂质20Fenofibrate Impurity 20
Fenofibrate Impurity 20
CAS No.51368-55-9
Chemical FormulaC7H13BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 21 structure
21
非诺贝特杂质21Fenofibrate Impurity 21
Fenofibrate Impurity 21
CAS No.60013-02-7
Chemical FormulaC13H8Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 24 structure
24
非诺贝特杂质24Fenofibrate Impurity 24
Fenofibrate Impurity 24
CAS No.10547-60-1
Chemical FormulaC14H11ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 25 structure
25
非诺贝特杂质25Fenofibrate Impurity 25
Fenofibrate Impurity 25
CAS No.61024-31-5
Chemical FormulaC17H15ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 26 structure
26
非诺贝特杂质26Fenofibrate Impurity 26
Fenofibrate Impurity 26
CAS No.2991460-92-3
Chemical FormulaC20H21ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 27 structure
27
非诺贝特杂质27Fenofibrate Impurity 27
Fenofibrate Impurity 27
CAS No.2304658-42-0
Chemical FormulaC20H21ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 28 structure
28
非诺贝特杂质28Fenofibrate Impurity 28
Fenofibrate Impurity 28
CAS No.134612-84-3
Chemical FormulaC13H9ClO3
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 29 structure
29
非诺贝特杂质29Fenofibrate Impurity 29
Fenofibrate Impurity 29
CAS No.16911-33-4
Chemical FormulaC25H19NO
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 30 structure
30
非诺贝特杂质30Fenofibrate Impurity 30
Fenofibrate Impurity 30
CAS No.34183-01-2
Chemical FormulaC13H8Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 31 structure
31
非诺贝特杂质31Fenofibrate Impurity 31
Fenofibrate Impurity 31
CAS No.388632-17-5
Chemical FormulaC20H21ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 33 structure
33
非诺贝特杂质33Fenofibrate Impurity 33
Fenofibrate Impurity 33
CAS No.217636-50-5
Chemical FormulaC34H28Cl2O7
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 34 structure
34
非诺贝特杂质34Fenofibrate Impurity 34
Fenofibrate Impurity 34
CAS No.55270-71-8
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 35 structure
35
非诺贝特杂质35Fenofibrate Impurity 35
Fenofibrate Impurity 35
CAS No.61002-52-6
Chemical FormulaC13H9ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 36 structure
36
非诺贝特杂质36Fenofibrate Impurity 36
Fenofibrate Impurity 36
CAS No.3033604-65-5
Chemical FormulaC16H15ClO3
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 37 structure
37
非诺贝特杂质37Fenofibrate Impurity 37
Fenofibrate Impurity 37
CAS No.60012-96-6
Chemical FormulaC17H15ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 39 structure
39
非诺贝特杂质39Fenofibrate Impurity 39
Fenofibrate Impurity 39
CAS No.31702-79-1
Chemical FormulaC21H22O7
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 42 structure
42
非诺贝特杂质42Fenofibrate Impurity 42
Fenofibrate Impurity 42
CAS No.60805-30-3
Chemical FormulaC13H8Cl2O2
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 43 structure
43
非诺贝特杂质43Fenofibrate Impurity 43
Fenofibrate Impurity 43
CAS No.217636-51-6
Chemical FormulaC20H21ClO4
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 44 structure
44
非诺贝特杂质44Fenofibrate Impurity 44
Fenofibrate Impurity 44
CAS No.1989-04-4
Chemical FormulaC15H15ClO
Purity>95%询价On request
10mg25mg50mg100mg
Fenofibrate Impurity 45 structure
45
非诺贝特杂质45Fenofibrate Impurity 45
Fenofibrate Impurity 45
CAS No.1989-02-2
Chemical FormulaC19H21ClO3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

非诺贝特 —— 研究文献与合成路线Fenofibrate — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 非诺贝特 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Fenofibrate. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets
    Kadav AA, Vora DN · Journal of pharmaceutical and biomedical analysis · 2008 · 被引 22cited 22
  2. Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation
    Park JS, Kang DH, Lee DH, et al. · Biochemical and biophysical research communications · 2015 · 被引 31cited 31
  3. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1
    Lan D, Silver DL · The Journal of biological chemistry · 2005 · 被引 30cited 30
  4. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation
    Sun Z, Xu D, Zhao L, et al. · British journal of pharmacology · 2022 · 被引 13cited 13
  5. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels
    Abdul-Hay SO, Edirisinghe P, Thatcher GR · Journal of neurochemistry · 2009 · 被引 12cited 12
  6. Univariate and multivariate assisted spectrophotometric methods for determination of rosuvastatin calcium and fenofibrate in bulk powders and tablets along with their degradation products
    Hegazy MA, Bakr MA, Badawey AM, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2021 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. NOVEL METHOD OF SYNTHESIZING FENOFIBRATE
    LUCAS BEATRICE · 公开号 CA2690869CA2690869 · 2009
  2. NOVEL METHOD OF SYNTHESIZING FENOFIBRATE
    LUCAS BEATRICE · 公开号 US2012065421US2012065421 · 2012
  3. NOVEL METHOD OF SYNTHESIZING FENOFIBRATE
    LUCAS BEATRICE · 公开号 KR20100036231KR20100036231 · 2010
  4. NOVEL METHOD OF SYNTHESIZING FENOFIBRATE
    LUCAS BEATRICE · 公开号 EP2170801EP2170801 · 2010
  5. METHOD FOR PREPARING PURE FENOFIBRATE
    TUBERTINI PAOLO, VECCHIO EMILIO · 公开号 JP2008266197JP2008266197 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

非诺贝特 杂质谱研究要点Fenofibrate — impurity profiling notes

下面这些是拿到 非诺贝特 的 38 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 38 impurity entries for Fenofibrate, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances